Literature DB >> 35584836

Multiple myeloma: what a non-haematologist should know.

Taran K Nandra1, Amarpreet Devi2, John R Jones3.   

Abstract

Multiple myeloma (MM) is a type of haematological bone marrow malignancy. Cancer Research UK reports that MM is the 18th most common cancer in the UK, accounting for 2% of all new cancer cases, yet, non-haematologists often lack familiarity with the pathology and initial investigations. This paper aims to demonstrate the diagnostic features, relevant investigations and basic management plan for the non-specialist. © Royal College of Physicians 2022. All rights reserved.

Entities:  

Keywords:  haematology; myeloma; non-specialist

Mesh：

Year:  2022        PMID： 35584836      PMCID： PMC9135076          DOI： 10.7861/clinmed.2022-0144

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   5.410


  5 in total

Review 1.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

2.  Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.

Authors:  Jonathan Sive; Kirsty Cuthill; Hannah Hunter; Majid Kazmi; Guy Pratt; Dean Smith
Journal:  Br J Haematol       Date:  2021-03-21       Impact factor: 6.998

Review 3.  Pathogenesis and treatment of renal failure in multiple myeloma.

Authors:  M A Dimopoulos; E Kastritis; L Rosinol; J Bladé; H Ludwig
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

4.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Graham H Jackson; Faith E Davies; Charlotte Pawlyn; David A Cairns; Alina Striha; Corinne Collett; Anna Hockaday; John R Jones; Bhuvan Kishore; Mamta Garg; Cathy D Williams; Kamaraj Karunanithi; Jindriska Lindsay; Matthew W Jenner; Gordon Cook; Nigel H Russell; Martin F Kaiser; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan
Journal:  Lancet Oncol       Date:  2018-12-14       Impact factor: 41.316

5.  Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Mark T Drayson; Stella Bowcock; Tim Planche; Gulnaz Iqbal; Guy Pratt; Kwee Yong; Jill Wood; Kerry Raynes; Helen Higgins; Bryony Dawkins; David Meads; Claire T Hulme; Irene Monahan; Kamaraj Karunanithi; Helen Dignum; Edward Belsham; Jeff Neilson; Beth Harrison; Anand Lokare; Gavin Campbell; Michael Hamblin; Peter Hawkey; Anna C Whittaker; Eric Low; Janet A Dunn
Journal:  Lancet Oncol       Date:  2019-10-23       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.